BMXMF Stock Chart & Stats
$106.66
--
Market closed
$106.66
--
Day’s Range― - ―
52-Week Range$73.40 - $152.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)41.00
Market Cap
$9.99B
Enterprise Value$7.90K
Total Cash (Recent Filing)$657.70M
Total Debt (Recent Filing)$421.80M
Price to Earnings (P/E)18.8
Beta0.33
Next Earnings
Mar 04, 2027EPS Estimate
2.93Next Dividend Ex-DateN/A
Dividend Yield1.28%
Share Statistics
EPS (TTM)3.93
Shares Outstanding118,361,220
10 Day Avg. Volume67
30 Day Avg. Volume41
Financial Highlights & Ratios
PEG Ratio-4.00
Price to Book (P/B)3.17
Price to Sales (P/S)3.20
P/FCF Ratio28.72
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$88.69Price Target Upside-16.85% Downside
Rating ConsensusHold
Number of Analyst Covering7
EPS Forecast (FY)5.02
Revenue Forecast (FY)$4.76B
Bulls Say, Bears Say
Bulls Say
Recurring-consumables Business ModelbioMérieux's installed-base + consumables model creates predictable, repeatable revenue as instruments drive ongoing reagent and kit purchases. That structural annuity supports durable margins, recurring cash flow and higher lifetime value per customer versus one-off product sellers.
Conservative Balance SheetA low debt-to-equity ratio and sizable equity base give bioMérieux financial flexibility to fund R&D, capital deployments and acquisitions without stressing liquidity. Conservative leverage reduces refinancing risk and supports resilience through industry cycles and slower organic growth periods.
Improving Free Cash FlowThe meaningful rebound in free cash flow in 2024–2025 strengthens internal funding for product development, installed-base expansion and shareholder returns. While prior volatility exists, the recent step-up indicates improved cash conversion that can sustainably support strategic investments.
Bears Say
Softening Revenue GrowthA decline in annual revenue in 2025 signals slowing top-line momentum that can impair long-term operating leverage. Slower organic growth pressures the installed-base expansion rate and reduces opportunities to boost recurring consumable volumes and expand margins via higher throughput.
Declining Return On EquityROE erosion from ~19% to ~10% reflects weaker profit generation relative to a larger capital base. Persistently lower capital efficiency can signal tougher competitive dynamics or margin pressure, limiting the company's ability to convert equity growth into proportionate shareholder returns.
Inconsistent Cash ConversionOperating cash flow covered well under 1x of reported earnings in 2024 and FCF was under half of earnings, indicating working-capital and cash-conversion volatility. Such inconsistency can constrain reliable reinvestment, dividends or M&A unless cash conversion stabilizes.
bioMerieux News
BMXMF FAQ
What was bioMerieux’s price range in the past 12 months?
bioMerieux lowest stock price was $73.40 and its highest was $152.00 in the past 12 months.
What is bioMerieux’s market cap?
bioMerieux’s market cap is $9.99B.
When is bioMerieux’s upcoming earnings report date?
bioMerieux’s upcoming earnings report date is Mar 04, 2027 which is in 204 days.
How were bioMerieux’s earnings last quarter?
bioMerieux released its earnings results on Jul 28, 2026. The company reported $2.296 earnings per share for the quarter, missing the consensus estimate of $2.342 by -$0.046.
Is bioMerieux overvalued?
According to Wall Street analysts bioMerieux’s price is currently Overvalued.
Does bioMerieux pay dividends?
bioMerieux pays a Annually dividend of $1.132 which represents an annual dividend yield of 1.28%. See more information on bioMerieux dividends here
What is bioMerieux’s EPS estimate?
bioMerieux’s EPS estimate is 2.93.
How many shares outstanding does bioMerieux have?
bioMerieux has 118,361,220 shares outstanding.
What happened to bioMerieux’s price movement after its last earnings report?
bioMerieux reported an EPS of $2.296 in its last earnings report, missing expectations of $2.342. Following the earnings report the stock price went up 5.856%.
Which hedge fund is a major shareholder of bioMerieux?
Currently, no hedge funds are holding shares in BMXMF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
bioMerieux
bioMérieux S.A. is a global entity operating across the Americas, Europe, the Middle East, Africa, and the Asia Pacific, specializing in the development and production of in vitro diagnostic solutions. The company's sophisticated systems utilize biological samples to identify infectious diseases, cardiovascular conditions, and various forms of cancer. Additionally, bioMérieux provides essential microbiological testing services for the manufacturing sectors, primarily serving the food, pharmaceutical, cosmetics, and veterinary industries. Its client base includes clinical and hospital laboratories, medical practitioners, blood banks, and industrial quality control facilities. Founded in 1963, originally under the name B-D Mérieux, bioMérieux S.A. maintains its headquarters in Marcy l'Etoile, France, and functions as a subsidiary of Institut Mérieux SA.
BMXMF Stock 12 Month Forecast
Average Price Target
$88.69
▼(-16.85% Downside)
Eurofins Scientific
―
Sartorius Stedim Biotech
―
Virbac SA
―
Eurofins-Cerep SA
―
Biosynex SA
―
Ownership Overview
―
Insiders
5.30% Mutual Funds
<0.01% Other Institutional Investors
90.77% Public Companies and
Individual Investors